Malignant obstruction of the inferior vena cava: clinical experience with the self-expanding Sinus-XL stent system

Anne Marie Augustin1, Leonie Johanna Lucius1, Annette Thurner1, Ralph Kickuth1

Received: 1 April 2022 / Revised: 8 June 2022 / Accepted: 8 June 2022 / Published online: 6 July 2022
© The Author(s) 2022

Abstract
Purpose To evaluate the technical and clinical outcome of Sinus-XL stent placement in patients with malignant obstruction syndrome of the inferior vena cava.
Methods Between October 2010 and January 2021, 21 patients with different malignant primary disease causing inferior vena cava obstruction were treated with Sinus-XL stent implantation. Procedural data, technical and clinical outcome parameters were retrospectively analyzed.
Results Technical success was 100%. Analysis of available manometry data revealed a significant reduction of the mean translesional pressure gradient following the procedure (p = 0.008). Reintervention rate was 4.8% (1/21). The available follow-up imaging studies showed primary and primary-assisted stent patency rates of 93% (13/14) and 100% (14/14), respectively. Major complications did not occur. The clinical success regarding lower extremity edema was 82.4% (14/17) for the first and 85.7% (18/21) for the last follow-up. Longer lengths of IVC obstruction were associated with reduced clinical improvement after the procedure (p = 0.025). Improvement of intraprocedural manometry results and lower extremity edema revealed only minor correlation. Ascites and anasarca were not significantly positively affected by the procedure.
Conclusion Sinus-XL stent placement in patients with malignant inferior vena cava obstruction showed high technical success and low complication rates. Regarding the clinical outcome, significant symptom improvement could be achieved in lower extremity edema, whereas ascites and anasarca lacked satisfying symptom relief. Based on our results, this procedure should be considered as a suitable therapy in a palliative care setting for patients with advanced malignant disease.

Keywords Endovascular · Inferior vena cava · Interventional procedures · Oncology · Palliative care · Stent

Introduction
In malignant inferior vena cava (IVC) obstruction, advanced primary malignancy or metastatic disease of organs surrounding the IVC lead to IVC compression, invasion or thrombus formation with impaired venous return to the heart [1]. Compared to malignant obstructions of the superior vena cava (SVC), IVC compression-syndrome is rare [2].

Symptoms of malignant IVC obstruction vary, depending on degree and level of obstruction, time of onset and duration of vessel compression [3, 4]. Patients may suffer from hypotension, tachycardia, lower extremity edema, anasarca, skin ulcerations and eczema, ascites as well as renal and hepatic insufficiency. Thus, in severe cases the quality of life and the capability of undergoing therapy may be considerably limited [5, 6].

Since symptoms of malignant infra-diaphragmatic IVC obstructions use to occur late in the course of an advanced malignant disease, therapy concepts are predominantly palliative [7]. These vulnerable patients are poor surgical candidates and non-invasive, medical therapies such as diuretics lack the desired efficacy. Hence, additional treatment strategies are required to palliate these patients sufficiently [8].

Percutaneous endovascular treatment of IVC obstructions with stent placement represents a minimally invasive alternative in terms of prompt hemodynamic therapy effect and fast symptom relief [9]. To date, only few data exist addressing the technical success of IVC stent placement, and even less regarding the clinical outcome of the treated patients. Therefore, the purpose of this study was to evaluate
our clinical experiences using the self-expanding Sinus-XL stent system (Optimed, Ettlingen, Germany) for treatment of patients with symptomatic IVC obstruction due to malignancies of various origin.

**Materials and methods**

**Study cohort**

A retrospective review of the archives of our interventional radiology department from October 2010 to January 2021 yielded the cases of 21 patients with malignant IVC obstructions (11 women and 10 men, median age 61.0; range 18–92 years), who underwent IVC stent implantation. In each case, we used the closed-cell designed, self-expanding nitinol Sinus-XL stent. Patients with benign IVC compression were excluded from the study. The requirement for consent from patients to be included in this retrospective study was waived by our institutional review board (No. 20211125 01). All patients were examined and treated as part of routine care and informed consent for the procedure was obtained before the procedure. Patients’ characteristics and underlying conditions are presented in Table 1.

IVC obstruction syndrome was based on primary tumor compression in five cases, whereas in 16 cases, significant IVC compression was caused by metastatic disease, including metastatic lymph nodes in seven, hepatic metastases in six and a combination of lymph node and hepatic metastases in three patients.

In each case, the indication for endovascular IVC stent implantation was approved by an interdisciplinary team consisting of interventional radiologists, oncologists as well as visceral and vascular surgeons. In 20 patients, stent placement was triggered by worsening of IVC obstruction symptoms. In one case, stent placement was performed as a preventive measure.

| Patient | Age | Gender | Primary diagnosis  | Cause of obstruction | Level of obstruction | Previous treatment | Subsequent treatment |
|---------|-----|--------|--------------------|----------------------|---------------------|-------------------|---------------------|
| 1       | 91  | F      | MM                 | Primary tumor        | Suprarenal          | RCTX              | –                   |
| 2       | 42  | F      | ACC                | Hepatic and lymphonodal metastasis | Intrahepatic to renal | CTX               | –                   |
| 3       | 44  | M      | NSCLC              | Hepatic and lymphonodal metastasis | Intrahepatic and renal | RCTX              | –                   |
| 4       | 35  | F      | B-ALL              | Lymphonodal          | Supra- and infrarenal | CTX               | RCTX               |
| 5       | 18  | M      | Testicular cancer  | Lymphonodal          | Renal to iliac      | CTX               | CTX                 |
| 6       | 64  | F      | ACC                | Primary tumor        | Intrahepatic to iliac | CTX               | CTX                 |
| 7       | 72  | M      | NHL                | Lymphonodal          | Supra- and infrarenal | CTX               | CTX                 |
| 8       | 61  | F      | NET Pancreas       | Hepatic metastasis   | Intrahepatic         | RCTX              | CTX                 |
| 9       | 61  | M      | NET Ileum          | Hepatic metastasis   | Intrahepatic         | CTX               | –                   |
| 10      | 53  | F      | Anal cancer        | Hepatic metastasis   | Intrahepatic         | RCTX              | –                   |
| 11      | 25  | F      | Leimyosarcoma      | Hepatic metastasis   | Intrahepatic         | RCTX              | CTX                 |
| 12      | 55  | F      | CCC                | Primary tumor        | Intrahepatic         | RCTX              | RCTX                |
| 13      | 72  | F      | AEG II/III         | Lymphonodal          | Intrahepatic         | RCTX              | –                   |
| 14      | 79  | F      | HCC                | hepatic metastasis   | Intrahepatic         | CTX               | CTX                 |
| 15      | 44  | M      | SCLC               | Hepatic and lymphonodal metastasis | Intrahepatic and infrarenal | RCTX              | –                   |
| 16      | 63  | M      | HCC                | Primary tumor        | Intrahepatic         | –                 | –                   |
| 17      | 57  | F      | NET unknown origin | Lymphonodal          | Supra- and infrarenal | RCTX              | RTX                 |
| 18      | 79  | M      | NET Ileum          | Lymphonodal          | Infrarenal to iliac  | RCTX              | –                   |
| 19      | 63  | M      | Liposarcoma        | Primary tumor        | Infrarenal to iliac  | RCTX              | CTX                 |
| 20      | 92  | M      | Gastric cancer     | Hepatic metastasis   | Intrahepatic to renal | –                 | –                   |
| 21      | 69  | M      | CUP                | Lymphonodal          | Infrarenal           | CTX               | CTX                 |

ACC adrenocortical carcinoma, B-ALL B-cell acute lymphoblastic lymphoma, CTX chemotherapy, CUP cancer of unknown primary, MM multiple myeloma, NET neuroendocrine tumour, NHL non-Hodgkin’s lymphoma, NSCLC non-small cell lung cancer, RTX radiotherapy, RCTX radiochemotherapy
Preprocedural imaging

For verification of IVC obstruction and procedure planning, 19 patients (90.5%) underwent abdominal contrast-enhanced computed tomography (CT), one patient received abdominal contrast-enhanced magnetic resonance imaging (MRI), and one patient was examined by ultrasound. Diagnostic imaging was performed at a median of 8 days (range 0–64 days) prior to the procedure.

Procedure

All procedures were performed by the same operator in our local angiography suite (Siemens, Axiom Artis Zee, Forchheim, Germany) via a transfemoral antegrade venous approach. In 20 cases, we used the right common femoral vein as access site. In one case, the left common femoral vein was accessed. IVC stenosis was passed with a 0.035-inch guide wire (Radifocus, Terumo, Tokyo) and a 5F selective angiography catheter (Berenstein configuration, Angio- dynamics, Queensbury, NY). IVC stenosis was confirmed by digital subtraction cavography via a 10F sheath (Check Flo, Cook, Bjaeverskov, Denmark). Prior to cavography, we exchanged the crossing guide wire and the selective catheter for a 0.035-inch support guide wire (Back-Up Meier, Boston Scientific, Natick, Mass) and a calibrated 5F pigtail catheter. We chose oversized self-expanding stents exceeding the normal IVC diameter by approximately 25–30%. The Sinus-XL stent is a laser-cutting nitinol stent compatible with a 10F sheath and a 0.035-inch guide wire available in eleven diameters (16–34 mm) and six lengths (30–100 mm).

After cannulation of the obstructed IVC segment, the stent system was introduced and deployed under fluoroscopic control. All patients had a bolus of 5000 units of unfractionated heparin intraprocedurally. Balloon predilatation was performed in four cases using different types of undersized balloons (Atlas®, Bard, Tempe, AZ; Zelos®, Optimed, Ettlingen, Germany; XXL® Boston Scientific, Maple Grove, MN). In nine cases more than one stent was required and implanted in an overlapping technique. In six cases (27.3%), cavography demonstrated relevant residual stenosis of the treated vessel segment, necessitating additional balloon dilatation. For post-dilatation we used undersized balloons (Atlas®, Bard, Tempe, AZ; Zelos®, Optimed, Ettlingen, Germany; Armada®, Abbott Vascular, Santa Clara, CA). A final cavogram was performed to proof sufficient stent expansion and recanalization of the stenotic IVC segment. Sheaths were removed and access site was closed by manual compression (Figs. 1, 2).

In nine patients, venous blood pressure measurements were performed during the intervention. At the discretion of the interventional radiologist, pressure gradients were measured across the stenotic segment before and after stent placement. Postinterventionally, the patients received a therapeutic PTT-adapted dose of low-molecular-weight heparin.

Fig. 1 25-year-old female patient with hepatic metastasis of a retroperitoneal leiomyosarcoma. a Preinterventionally performed coronal contrast-enhanced computed tomography demonstrates high-grade stenosis of the IVC in the intrahepatic segment due to the intrahepatic tumor masses. b Corresponding cavography depicts the extent of the central venous obstruction and collateralization. c Fluoroscopic approval of the successful deployment of the Sinus-XL stent within in the malignant stenosis. d Cavography of the IVC after stent deployment demonstrates restored patency with reduced blood flow via collateral vessels.
for 7 days, followed by conversion to long-term anticoagulation with enoxaparin or aspirin.

**Endpoint definition and data gathering**

Two authors reviewed the patients’ medical and radiologic records to gather information on the technical and clinical success of the interventions. As far as possible, missing data were added by telephone interviews with patients and referring physicians. Technical success, clinical success and safety were defined as primary endpoints.

Technical success was designated as successful deployment of the stent within the obstructive lesion accompanied by significant improvement of blood flow in the stenotic IVC segment and by reduced blood flow via collateral vessels. Clinical success was determined as the improvement of the patient’s symptoms. The introduction of a scoring system allowed the quantification of clinical success assessing the main manifestations, i.e. edema, anasarca and ascites before and after the procedure. To this end, we modified previously published grading systems [6, 10, 11].

Lower body edema was graded as follows: 0 for absence of edema, 1 point for mild edema, 2 points for moderate edematous swelling, 3 points for severe swelling impeding the palpation of foot pulses without pain and immobility and 4 points for massive edematous swelling causing pain and immobility. The edema distribution was scored, ranging from 0.5 points for swelling of the feet to 2 points for the genitals being involved. The presence of complicating factors, for example ulcerations, were graded with an additional point resulting in a maximum score of 7 points. Progress of the edema severity during the follow-up period was rated with another 0.5 points, whereas improvement was assessed with minus 0.5 points. The rating of lower body edema was based on the patients’ clinical reports at three time points during the follow-up period.

Ascites was scored by means of a four-point-scale: 0 for absence of ascites up to 3 indicating the necessity of paracentesis. Cross-sectional imaging and the patients’ data including paracentesis reports allowed the assessment of ascites. After the procedure, reassessment was performed at two time points during the follow-up period. During the follow-up period, a slight progression or reduction was rated by addition or subtraction of 0.5 points, a severe progression or reduction of ascites by addition or subtraction of 1 point.

Scoring of anasarca was based on cross-sectional studies exclusively. Rating was as follows: 0 point for the absence of
anasarca, 1 point for slight anasarca and 2 points for severe anasarca. Anasarca scoring during the follow-up was executed analogously to the scoring of ascites.

Considering the procedural safety, complications were classified according to the reporting standards of the Society of Interventional Radiology [12].

Secondary endpoints were defined as procedural parameters, including the number and size of the implanted stents, procedure duration, fluoroscopy time, and radiation exposure in terms of the dose area product. In nine patients, pressure gradient measurements were performed before and after the stenting and the results were also added to the secondary endpoints. Furthermore, lengths of the VCI obstruction were measured based on the intraprocedural cavography as well as cross-sectional imaging.

As another secondary endpoint, we analyzed luminal expansion and stent patency. A residual stenosis of less than 50% on cross-sectional imaging is considered as luminal expansion. Patency was defined as preserved stent perfusion documented by contrast-enhanced imaging or duplex ultrasound. Luminal expansion measurements were available in 15 cases, while contrast enhanced images enabling the assessment of patency were only available in 14 cases. Assisted primary functional patency was defined as patency subsequent to another interventional treatment.

Statistical analysis

Descriptive data were presented as means ± standard deviation (SD) for normally distributed variables or medians with ranges for non-normalized variables, if appropriate; categorical data were expressed as counts and percentages with n (%). With regard to assessment of normality, the Anderson–Darling test was used rejecting the hypothesis of normality when the \( p \) value is less or equal to 0.05. The Wilcoxon test and the Mann–Whitney U test were used for comparison of the pre- and postinterventional data or described subgroups. Kaplan–Meier analysis including the log rank test was used to analyse patients’ survival and stent patency rates.

Correlation analysis of ordinal and metrical data were performed with the test according to Spearman for non-normalized variables. For all evaluations, a \( p \) value less than 0.05 was considered to indicate significant differences. Statistical analysis and the evaluation of the data were performed with a specialized computer algorithm (Microsoft Excel V1908 and RStudio 1.2.5033).

Follow-up

Clinical examination was performed in those patients who returned for routine follow-up control in our outpatient clinic. All patients were advised to immediately contact the outpatient clinic at onset of new or worsening symptoms. Imaging follow-up was conducted in the context of re-evaluation of the underlying malignant disease. Median clinical follow-up was 65 days (range 1–790 days) and 10 days (range 0–185) prior to the patients’ decease. The average time between procedure and the last cross-sectional imaging follow-up amounted to 66 days (range 1–775 days) or 35 days (range 1–179 days) between the last imaging follow-up and the patient’s decease.

Results

Technical success and procedural data

In all procedures, correct stent placement led to anatomical improvement of the outflow situation with marked reduction of collateral vessel flow. The technical success rate was 100% (21/21). In one case (4.8%), a reintervention was necessary three days after the procedure. This patient presented persisting edematous swelling of the lower extremities. Duplex ultrasound revealed absence of perfusion in the IVC due to significant stent compromise at the proximal end. Subsequently, the patient was transferred to the angiography suite where fluoroscopy proved the Sinus-XL stent to be subtotally compressed. Since the stent lumen could not be restored by balloon angioplasty, the stent was prolonged by a second Sinus-XL stent. This measure provided sufficient lumen restoration. As a result of this reintervention, the patient experienced a distinct clinical improvement and complete regression of the lower body edema until he deceased 389 days after the primary procedure.

Including the case of reintervention, a total of 37 Sinus XL stents were implanted (median 1; range 1–4 stents). Balloon dilatation before stent deployment was performed in 18.2% of the procedures (4/22). Pressure gradient data before and after the revascularization were available in nine of the included cases (42.9%). In these cases, mean pressure gradients across the stenotic segment decreased with statistical significance from 12.7 ± 6.5 to 3.4 ± 3.0 mmHg after the stent implantation, resulting in a mean pressure gradient reduction of 64% (mean reduction 9.3 mmHg; \( p = 0.008 \)). In eight cases, the stents covered the renal vein ostia without causing a deterioration of the renal function. Procedural data are reflected in Table 2.

Stent patency

Six patients died from progressive malignant disease within four weeks after the procedure. Therefore, assessment of luminal expansion was feasible in 15 patients (71.4%). Since only non-enhanced CT imaging was available in one case, we evaluated the stent patency in 14 patients. The follow-up
revealed a primary stent patency of 92.9%. In one case, rein-
tervention resulted in restoration of stent patency, leading to
a primary assisted patency rate of 100% (14/14). In 46.7%
of patients (7/15) we recorded stent lumen compromise of
more than 50%. Information on the distribution of luminal
expansion during the follow-up examinations is presented
in Table 3.

**Complications**

Major complications in terms of stent dislocation, stent
migration or vascular rupture were not observed during the
follow-up period. A total of three minor complications
were documented (14.3%). In one case, the patient presented
slight bleeding from the puncture site, which was treated
successfully by manual compression (SIR complication cat-
egory B). One patient complained of abdominal pain after
the procedure, which was successfully treated by adjustment
of the analgetic therapy (SIR complication category B). In
another patient with abdominal pain subsequently to the pro-
cedure the complaints ceased without any further therapy
(SIR complication category A).

**Assessment of clinical success**

The included 21 patients presented several clinical symp-
toms before treatment. 20 patients (95.2%) suffered from
edema of the lower extremities, 18 patients (85.7%) from
ascites and 18 patients from anasarca (85.7%). The majority
of our patients (16/21; 76.2%) suffered from a combination
of all three assessed symptoms. Summarized data regarding
the clinical outcome are shown in Table 4.

**Lower extremity edema**

Data regarding lower extremity edema prior to the proce-
dure were available in all 21 cases. Before the procedure, the
median score for edema was 4.5 points (range 0–7 points).
66.7% of our patients (14/21) were rated with more than 4
points. Complicating conditions, leading to an additional
rating point, were present in seven patients and included
edematous dermatitis in four patients (19.1%), ulceration of
the lower extremities in two patients (9.5%) and erysipelas
in one patient (4.8%). The clinical success of the procedure
with respect to symptomatic edematous swelling at the first
follow-up time point was 82.4% (14/17). Complete regres-
sion of all preexisting complicating conditions were found
during the follow-up period. Among 20 patients with lower
extremity edema prior to the procedure, eight showed com-
plete edema regression (40.0%).

Involvement of the hepatic segment in IVC obstruction
did not show significant correlation with the degree of edema
score reduction ($p = 0.691$). Spearman correlation analysis
resulted in a significant correlation of stenosis length and
clinical improvement. Consequently, a higher score point
reduction was recorded for less than 80 mm obstruction
lengths (correlation = −0.499; $p = 0.025$). We did not find a
significant correlation of intraprocedural pressure gradient
reduction and clinical outcome regarding lower extremity
edema at the last follow-up (correlation = 0.293; $p = 0.482$).

**Ascites**

Preinterventional ascites score with a median of 1 (range
0–3) points was assessed in all patients within a median
of 8 days prior to the procedure (range 1–28 days). 38.1%
(8/21) of the patients had a score of 2 points. In two patients,
follow-up data in terms of ascites was not available. Over-
all, postprocedural score points based on the last follow-
up examination revealed a worsening of ascites with sig-
ificantly higher median score points of 2 ($p = 0.001$). Four

| Table 2 Procedural data |  |
|------------------------|--|
| Number of stents per patient | $n$ | % |
| 1 | 13 | 59.1 |
| 2 | 5 | 22.7 |
| 3 | 2 | 9.1 |
| 4 | 2 | 9.1 |
| Procedure time (min) | Median | Range |
| Radiation exposure data | Median | Range |
| Dose area product (Gy*cm^2) | 46.1 | 10.3–805.4 |
| Fluoroscopy time (s) | 5.4 | 2.2–20.3 |
| Iodinated contrast agent (ml) | Median | Range |
| VCI obstruction length (mm) | Median | Range |
| Stent diameter (mm) | Median | Range |
| Stent length (mm) | Median | Range |

| Table 3 Luminal expansion of the Sinus-XL stent during the follow-up period ($n = 15$) | Degree of luminal expansion (%) | Number of cases ($n$) |
|-----------------------------------------|----------------|----------------|
| 100 | 3 |
| 80–100 | 1 |
| 70–80 | 1 |
| 60–70 | 2 |
| 50–60 | 1 |
| 30–40 | 1 |
| 20–30 | 2 |
| 20–10 | 1 |
| <10 | 3 |
patients received paracentesis during the follow-up period (19.1%).

**Anasarca**

Evaluation of preinterventional anasarca was feasible in all included patients, resulting in a median of 1.0 point (range 0–2.0 points), with 47.6% (10/21) being rated with 2 points. Assessment of postinterventional anasarca was possible in 14 patients. Among those patients, only seven patients underwent more than one follow-up imaging, thus in 7 out of 14 patients the first and last follow-up refers to the same score. Even if a slight improvement of anasarca could be documented during the follow-up period, median score points did not change significantly. As a result, the clinical success rate concerning anasarca was 42.9% including a complete regression in 9.1% (Fig. 3).

**Survival analysis**

During the first 30 days after the procedure, 33.3% of the treated patients (7/21) deceased. Within the follow-up period, all included patients died from the underlying advanced malignant disease (Fig. 4). Median survival time of the patients was 81 days after the procedure (range 4–805 days). Compared to the male patients, the median survival time of the female patients revealed to be 37 days shorter (median 75.0; range 4–152 days vs. median 112 days; range 1–790 days).

|        | n  | Median score points | Range score points | p value | Clinical success (%) | Clinical success (n) | Median follow-up duration (d) |
|--------|----|---------------------|--------------------|---------|----------------------|---------------------|-------------------------------|
| **Edema** |    |                     |                    |         |                      |                     |                               |
| Before  | 21 | 4.5                 | 0–7                |         |                      |                     |                               |
| First follow-up | 17 | 3.5                 | 2.5–6.5            | <0.001  | 82.4                 | 14/17               | 2 (1–3)                       |
| Last follow-up | 21 | 2.5                 | 0–6.5              | <0.001  | 85.7                 | 18/21               | 65 (1–790)                    |
| **Ascites** |    |                     |                    |         |                      |                     |                               |
| Before  | 21 | 1.0                 | 0–3                |         |                      |                     |                               |
| First follow-up | 19 | 1.0                 | 0–3                | 0.172   | 5.3                  | 1/19                | 8 (1–228)                     |
| Last follow-up | 19 | 2.0                 | 0–3                | 0.001   | 0                    | 0/19                | 64 (1–775)                    |
| **Anasarca** |    |                     |                    |         |                      |                     |                               |
| Before  | 21 | 1.0                 | 0–2                |         |                      |                     |                               |
| First follow-up | 14 | 1.0                 | 0–2                | 0.125   | 42.9                 | 6/14                | 20 (1–228)                    |
| Last follow-up | 14 | 1.0                 | 0–2                | 0.377   | 42.9                 | 6/14                | 66 (1–775)                    |

Fig. 3 Development of score points during the study period
Patients with IVC occlusion at the level of the intrahepatic vessel segment showed shorter survival times compared to those without involvement of the intrahepatic segment (median 66.0; range 4–389 days vs. median 133.0; range 14–805 days; \( p = 0.168 \)). Survival time revealed to be longer in patients with adjuvant oncologic treatment after IVC stenting (median 115; range 66–805 days vs. median 18; range 4–27 days; \( p = 0.247 \)). Nevertheless, none of those trends reached statistical significance.

**Discussion**

To our knowledge, to date our study is the first to be characterized by both, the utilization of the same closed-cell designed stent type throughout all the interventions, and the same experienced interventional radiologist performing all the procedures. In the field of malignant SVC obstructions, the application of the laser-cut nitinol Sinus-XL stent has already reached high levels of feasibility, safety, and technical success [13].

Patients with malignant IVC obstruction are predominantly characterized by advanced and incurable tumor stages, which is also reflected by the noticeable short survival times found in our study collective [14]. Given this fact, studies dealing with the symptomatic treatment of these patients can only be carried out to a limited extent and commonly lack long-term outcome analysis [4]. Studies addressing IVC stenting in particular remain limited and are commonly reported in the context of heterogeneous patient cohorts including SVC obstructions as well [9, 15–17]. One major reason for this fact is that malignant IVC obstruction is a rare condition [18].

As an alternative to IVC stenting, the use of chemotherapy or radiotherapy might achieve some degree of symptom relief, but presupposes a sufficient sensitivity of the underlying malignancy towards the treatment. Taken the acuteness of severe IVC compression symptoms into account, a successful, immediate therapy response due to IVC stenting offers a promising tool to palliate these critically ill patients [19, 20]. In our study, patients with subsequent radiotherapy and/or chemotherapy following stent implantation experienced a better outcome in terms of longer survival times, which agrees with other results regarding SVC stenting, even if this trend did not reach statistical significance [20, 21]. In this vulnerable patient collective, invasive surgical resection techniques are mostly not an option owing to the high operative risk [22]. The potentially fast implementation is one of the main advantages of the described procedure. In our study collective, the average procedure time amounted...
to 26 min which is considerably shorter than in previously published studies. This is supposed to be a result of the operator’s experience [10].

The present study focuses on the clinical outcome. In contrast to previously published data, radiological imaging was also included in the assessment of clinical success. Furthermore, a detailed, point-based score graduation was developed to assess both, the initial assessment of clinical status, as well as the course of symptoms. Overall, our results suggest that IVC stenting effectively alleviates lower extremity edema, which is one of the major symptoms associated with IVC obstruction. On the other hand, ascites and anasarca revealed only to be slightly influenced by stent treatment. Ascites and anasarca may be caused by a variety of pathologic conditions, such as disturbed venous outflow, impaired liver function in extended hepatic metastasis, peritoneal carcinomatosis, or cardiac insufficiency [23]. Therefore, the amount of ascites or anasarca can hardly be influenced by IVC stent placement as it is evidenced by our study results. Oppositely, even if edema can also be the result of different pathologic imbalances, it is most often based on a disturbed venous outflow, especially when being localized in a circumscribed area.

We stated that the overstenting of the renal vein ostia did not lead to an elevation of creatinine levels. Thus, we suppose that the stent strut gaps enable the renal venous outflow to be sufficiently preserved. Even if renal vein ostia overstenting causes acute venous outflow blockage, we assume that the renal venous blood finds its way through collateral pathways, for example through the periureteric venous plexus and the left gonadal vein [1, 24].

Compared to previously published data, the rate of reinterventions revealed to be relatively low (4.8%) with only one case necessitating early restoration of the stent lumen. For example, Fatima et al. reported a reintervention rate of 14.3% (4/28) after stenting in chronic thrombotic IVC occlusion [25]. Furthermore, previously reported severe procedure related complications, e.g. pulmonary edema, pulmonary embolism and stent fracture, did not occur in our study [6, 11, 26]. Intraprocedural and long-term stent migration as reported in other studies were not encountered in our case series [8, 13].

In accordance with Mokry et al., who implanted Sinus-XL stents in patients with superior vena cava compression syndrome, we used an undersized balloon for postdilatation, since the high radial force of the self-expanding Sinus-XL stent requires postdilatation only at the level of the tumor stenosis maximum [13]. In our experience, the use of balloons equal or above the reference vessel diameter for postdilation may be accompanied by stent recoiling at the level of the tumor maximum. Moreover, we hypothesize that the use of undersized balloons may prevent excessive tumor ingrowth.

It remains a matter of debate, whether covered stents should be preferred. Gwon et al. reported significant longer patency rates following covered stent placement in the treatment of SVC obstruction, thus the use of the non-covered Sinus-XL stent in the treatment of malignant IVC obstruction can be questioned [27]. However, even if the covered stenting might be an advantage in view of stent patency, the fact that a bare-metal design allows flow preservation via renal veins and collateral vessels can be considered as prevailing benefit.

The present study underlies different limitations. First, the study design is retrospective, and the number of included patients is limited. In synopsis with the patients’ critical condition, clinical and radiological follow-up examinations are inconsistent and partly incomplete. Second, the included patient collective is heterogeneous regarding the underlying malignant disease, the level of venous obstruction, and previously as well as subsequently received treatment. The lack of established criteria in the assessment of IVC symptoms represents another a general obstacle in a reliable and applicable outcome evaluation. The application of clinical scores, especially in a retrospective rating design, is subjective and thus impedes the comparison of the respective study results. Even though malignant IVC obstruction is rare and the analyzed patient collective is small, our study offers further insights into the technical aspects and the clinical outcome of the described procedure. To gain more detailed and transferable data, a larger and multicentric study applying a consensus-reading of a standardized score rating system would be desirable. Randomization might additionally facilitate the comparison of different stent types.

Based on our data, the utilized nitinol stent gathers the following advantages. The Sinus-XL stent appears to provide a patency comparable to other stent types. Concerning luminal expansion, comparable data are not available. However, contrary to balloon expandable stents, the self-expanding, closed-cell designed Sinus-XL stent is characterized by a higher radial force delivering increased resistance against tumor compression [28]. Further, we did not observe the foreshortening effect reported in the context of the WALLSTENT implantation [4, 13, 15, 29–31]. With respect to luminal tumor ingrowth, the nitinol Sinus-XL stent offers more resistance due to its close-meshed stent design compared to coarse-meshed designed stents, e.g. the self-expanding stainless-steel Gianturco stent. In addition, the Gianturco stent revealed only little resistance against eccentric tumor compression, which questions its suitability in the treatment of malignant IVC outflow obstruction [32, 33].

In conclusion, IVC stent implantation utilizing the Sinus-XL system is a feasible, effective and safe minimally invasive procedure, enabling significant clinical improvement of lower extremity edema in patients suffering from malignant
IVC obstruction syndrome. In contrast, a relevant benefit concerning ascites and anasarca was not observed. In this vulnerable patient cohort, the minimally invasive procedure offers excellent technical success rates, prompt clinical success and a low complication rate. Therefore, it is considered suitable in a palliative care setting. Due to the limited life expectancy, the procedures’ long-term results remain insufficiently elucidated.

Author contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by RK, AMA and LJL. The first draft of the manuscript was written by AMA and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Conflict of interest The authors declare that they have no competing interests.

Ethical approval The study protocol was approved by the Ethics Committee of University Hospital of Würzburg and made in accordance with the ethical standards laid down in the declaration of Helsinki.

Consent to participate The need for informed consent was waived due to the retrospective design of the study.

Consent for publication All authors have read, reviewed, and approved of this manuscript for publication in its present form.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sonin AH, Mazer MJ, Powers TA (1992) Obstruction of the inferior vena cava: a multiple-modality demonstration of causes, manifestations, and collateral pathways. Radiographics 12:309-322. https://doi.org/10.1148/radiographics.12.2.1561419
2. Fagedet D, Thony F, Timsit JF et al. (2013) Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. Cardiovasc Intervent Radiol 36:140-149. https://doi.org/10.1007/s00270-011-0310-z
3. Raju S, Hollis K, Neglen P (2006) Obstructive lesions of the inferior vena cava: clinical features and endovenous treatment. J Vasc Surg 44:820-827. https://doi.org/10.1016/j.jvs.2006.05.054
4. Friedman T, Quencer KB, Kishore SA et al. (2017) Malignant Venous Obstruction: Superior Vena Cava Syndrome and Beyond. Semin Intervent Radiol 34:398-408. https://doi.org/10.1055/s-0037-1608863
5. Hartley JW, Awrich AE, Wong J et al. (1986) Diagnosis and treatment of the inferior vena cava syndrome in advanced malignant disease. Am J Surg 152:70-74. https://doi.org/10.1016/0002-9610(86)90145-5
6. Brountzos EN, Binkert CA, Panagiotou IE et al. (2004) Clinical outcome after intrahepatic venous stent placement for malignant inferior vena cava syndrome. Cardiovasc Intervent Radiol 27:129-136. https://doi.org/10.1007/s00270-003-0009-x
7. Epelboym Y, Stecker MS, Fan CM et al. (2020) Treatment of malignant inferior vena cava obstruction with Gianturco-Rosch-Z stents: a single center 13-year experience. Clin Imaging 59:95-99. https://doi.org/10.1016/j.clinimag.2019.09.015
8. Kuettting D, Thomas D, Wilhelm K et al. (2017) Endovascular Management of Malignant Inferior Vena Cava Syndromes. Cardiovasc Intervent Radiol 40:1873-1881. https://doi.org/10.1007/s00270-017-1740-z
9. Yamagami T, Nakamura T, Kato T et al. (2002) Hemodynamic changes after self-expandable metallic stent therapy for vena cava syndrome. AJR Am J Roentgenol 178:635-639. https://doi.org/10.2214/ajr.178.3.1780635
10. Kishi K, Sonomura T, Fujimoto H et al. (2006) Physiologic effect of stent therapy for inferior vena cava obstruction due to malignant liver tumor. Cardiovasc Intervent Radiol 29:75-83. https://doi.org/10.1007/s00270-004-0324-x
11. Devcic Z, Techasith T, Banerjee A et al. (2016) Technical and Anatomic Factors Influencing the Success of Inferior Vena Cava Stent Placement for Malignant Obstruction. J Vasc Interv Radiol 27:1350-1360 e1351. https://doi.org/10.1016/j.jvir.2016.02.030
12. Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 14:199-202. https://doi.org/10.1097/01.rvi.0000044584.83406.3e
13. Mokry T, Bellemann N, Sommer CM et al. (2015) Retrospective study in 23 patients of the self-expanding sinus-XL stent for treatment of malignant superior vena cava obstruction caused by non-small cell lung cancer. J Vasc Interv Radiol 26:357-365. https://doi.org/10.1097/jvir.0000000000000354
14. Maleux G, Vertenten B, Laenen A et al. (2016) Palliative endovascular treatment of cancer-related iliac caval obstructive disease: technical and clinical outcomes. Acta Radiol 57:451-456. https://doi.org/10.1177/0284185115582059
15. Chacon Lopez-Muniz JJ, Garcia Garcia L, Lanciego Perez C et al. (1997) Treatment of superior and inferior vena cava syndromes of malignant cause with Wallstent catheter placed percutaneously. Am J Clin Oncol 20:293-297. https://doi.org/10.1097/00000421-199706000-00018
16. Irving JD, Dondelinger RF, Reidy JF et al. (1992) Gianturco self-expanding stents: clinical experience in the vena cava and large veins. Cardiovasc Intervent Radiol 15:328-333. https://doi.org/10.1007/BF02733958
17. Takeuchi Y, Arai Y, Sone M et al. (2019) Evaluation of stent placement for vena cava syndrome: phase II trial and phase III randomized controlled trial. Support Care Cancer 27:1081-1088. https://doi.org/10.1007/s00520-018-4397-5
18. Klein-Weigel PF, Elitok S, Rutloff A et al. (2021) Inferior vena cava syndrome. Vasa 50:250-264. https://doi.org/10.1024/0301-1526/a000919

19. Ganeshan A, Hon LQ, Warakaulle DR et al. (2009) Superior vena cava stenting for SVC obstruction: current status. Eur J Radiol 71:343-349. https://doi.org/10.1016/j.ejrad.2008.04.014

20. Nicholson AA, Ettles DF, Arnold A et al. (1997) Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 8:781-788. https://doi.org/10.1016/s1051-0443(97)70660-2

21. Nagata T, Makutani S, Uchida H et al. (2007) Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc Intervent Radiol 30:959-967. https://doi.org/10.1007/s00270-007-9088-4

22. Hemming AW, Langham MR, Reed AI et al. (2001) Resection of the inferior vena cava for hepatic malignancy. Am Surg 67:1081-1087; discussion 1087-1088.

23. Cavazzoni E, Bugiantella W, Graziosi L et al. (2013) Malignant ascites: pathophysiology and treatment. Int J Clin Oncol 18:1-9. https://doi.org/10.1007/s10147-012-0396-6

24. Kapur S, Paik E, Rezaei A, Vu DN (2010) Where there is blood, there is a way: unusual collateral vessels in superior and inferior vena cava obstruction. Radiographics 30:67-78. https://doi.org/10.1148/rg.301095724

25. Fatima J, AlGaby A, Bena J et al. (2015) Technical considerations, outcomes, and durability of inferior vena cava stenting. J Vasc Surg Venous Lymphat Disord 3:380-388. https://doi.org/10.1016/j.jvsv.2015.04.001

26. Yamagami T, Nakamura T, Kin Y et al. (2003) Fatal complications after self-expandable metallic stent placement for inferior vena cava syndrome. Cardiovasc Intervent Radiol 26:400-402. https://doi.org/10.1007/s00270-003-0508-9

27. Gwon DI, Ko KY, Kim JH et al. (2013) Malignant superior vena cava syndrome: a comparative cohort study of treatment with covered stents versus uncovered stents. Radiology 266:979-987. https://doi.org/10.1148/radiol.12120517

28. Andersen PE, DuVnjak S (2014) Palliative treatment of superior vena cava syndrome with nitinol stents. Int J Angiol 23:255-262. https://doi.org/10.1055/s-0034-1383432

29. Entwisle KG, Watkinson AF, Hibbert J, Adam A (1995) The use of the Wallstent endovascular prosthesis in the treatment of malignant inferior vena cava obstruction. Clin Radiol 50:310-313. https://doi.org/10.1016/s0009-9260(05)83422-1

30. Lanciego C, Pangua C, Chacon JJ et al. (2009) Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome. AJR Am J Roentgenol 193:549-558. https://doi.org/10.2214/AJR.08.1904

31. Zamora CA, Sugimoto K, Mori T et al. (2005) Use of the wallstent for symptomatic relief of malignant inferior vena cava obstructions. Radiat Med 23:380-385.

32. Flueckiger F, Sternthal H, Klein GE et al. (1994) Strength, elasticity, and plasticity of expandable metal stents: in vitro studies with three types of stress. J Vasc Interv Radiol 5:745-750. https://doi.org/10.1016/s1051-0443(94)71594-3

33. Tacke J, Antonucci F, Stuckmann G et al. (1994) [The palliative treatment of venous stenoses in tumor patients with self-expanding vascular prostheses]. Rofo 160:433-440. https://doi.org/10.1055/s-2008-1032454

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.